Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
- 2 February 2006
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 367 (9509), 475-481
- https://doi.org/10.1016/s0140-6736(06)68076-8
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus MonkeysJournal of Virology, 2005
- Evolution of H5N1 Avian Influenza Viruses in AsiaEmerging Infectious Diseases, 2005
- Development of nonhuman adenoviruses as vaccine vectorsVaccine, 2005
- Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in cultureBiochemical and Biophysical Research Communications, 2004
- Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humansVaccine, 2004
- Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccineVirus Research, 2004
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001
- A High-Efficiency Cre/loxP-Based System for Construction of Adenoviral VectorsHuman Gene Therapy, 1999
- Characterization of an Avian Influenza A (H5N1) Virus Isolated from a Child with a Fatal Respiratory IllnessScience, 1998
- Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virusNature, 1978